Physician profile
Michael Carter
NPI 1922006212
$2,415.40
in general payments reported to CMS, 2019-2025
12 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $534 · 2022: $520 · 2023: $533 · 2024: $512 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,336 · Education: $25.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,335.95 |
| Education | $25.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $937.83 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $666.28 | 2021-2025 | |
| Lilly USA, LLC | $349.13 | 2021-2024 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.89 | 2022-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $92.90 | 2021-2024 | Trintellix |
| Glaxosmithkline, LLC. | $77.70 | 2021-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.34 | 2023-2024 | Xifaxan |
| Novo Nordisk INC | $36.48 | 2023-2024 | Ozempic, Rybelsus |
| Amgen INC. | $22.29 | 2025 | Krystexxa |
| Biohaven Pharmaceuticals, INC. | $15.38 | 2021 | |
| Axsome Therapeutics, INC. | $13.39 | 2024 | Auvelity |
| Corium, LLC | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.